The caspase inhibitor IDN-6556 (PF3491390) improves marginal mass engraftment after islet transplantation in mice

Surgery

Volumn 150, Issue 1, 2011, Pages 48-55

  McCall, Michael ^a   Toso, Christian ^a,b   Emamaullee, Juliet ^a   Pawlick, Rena ^a   Edgar, Ryan ^a   Davis, Joy ^a   Maciver, Allison ^a   Kin, Tatsuya ^b   Arch, Robert ^c   Shapiro, A M James ^a,d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c PFIZER INC   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE INHIBITOR; EMRICASAN; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE COMPARISON; ENGRAFTMENT; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; CASPASES; CYSTEINE PROTEINASE INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TOLERANCE TEST; GRAFT ENHANCEMENT, IMMUNOLOGIC; GRAFT SURVIVAL; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PENTANOIC ACIDS; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, ISOGENEIC;

EID: 79959364964     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2011.02.023     Document Type: Article

References (31)

1. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230-8. (Pubitemid 30490390)
2. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006;355:1318-30. (Pubitemid 44465460)
3. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005;54:2060-9. (Pubitemid 40911269)
4. Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005;293:830-5. (Pubitemid 40250366)
5. Koh A, Senior P, Salam A, Kin T, Imes S, Dinyari P, et al. Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success. Transplantation 2010;89:465-71.
6. Emamaullee JA, Shapiro AM. Factors influencing the loss of beta-cell mass in islet transplantation. Cell Transplant 2007;16:1-8. (Pubitemid 46516652)
7. Korsgren O, Lundgren T, Felldin M, Foss A, Isaksson B, Permert J, et al. Optimising islet engraftment is critical for successful clinical islet transplantation. Diabetologia 2008;51:227-32.
8. Biarnés M, Montolio M, Nacher V, Raurell M, Soler J, Montanya E. Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes 2002;51:66-72. (Pubitemid 34517981)
9. Berney T, Mamin A, James Shapiro AM, Ritz-Laser B, Brulhart MC, Toso C, et al. Detection of insulin mRNA in the peripheral blood after human islet transplantion predicts deterioration of metabolic control. Am J Transplant 2006;6:1704-11. (Pubitemid 43945813)
10. Eriksson O, Eich T, Sundin A, Tibell A, Tufveson G, Andersson H, et al. Positron emission tomography in clinical islet transplantation. Am J Transplant 2009;9:2816-24.
11. Emamaullee J, Liston P, Korneluk RG, Shapiro AM, Elliott JF. XIAP overexpression in islet beta-cells enhances engraftment and minimizes hypoxia-reperfusion injury. Am J Transplant 2005;5:1297-305. (Pubitemid 40839417)
12. Emamaullee JA, Rajotte RV, Liston P, Korneluk RG, Lakey JR, Shapiro AM, et al. XIAP overexpression in human islets prevents early posttransplant apoptosis and reduces the islet mass needed to treat diabetes. Diabetes 2005;54:2541-8. (Pubitemid 41233574)
13. Emamaullee JA, Stanton L, Schur C, Shapiro AM. Caspase inhibitor therapy enhances marginal mass islet graft survival and preserves long-term function in islet transplantation. Diabetes 2007;56:1289-98. (Pubitemid 46715609)
14. Emamaullee JA, Davis J, Pawlick R, Toso C, Merani S, Cai SX, et al. The caspase selective inhibitor EP1013 augments human islet graft function and longevity in marginal mass islet transplantation in mice. Diabetes 2008;57:1556-66.
15. Linton SD, Aja T, Armstrong RA, Bai X, Chen LS, Chen N, et al. First-in-class pan caspase inhibitor developed for the treatment of liver disease. J Med Chem 2005;48:6779-82. (Pubitemid 41533098)
16. Shapiro AM, Gallant H, Hao E, Wong J, Rajotte R, Yatscoff R, et al. Portal vein immunosuppressant levels and islet graft toxicity. Transplant Proc 1998;30:641. (Pubitemid 28207334)
17. Desai NM, Goss JA, Deng S, Wolf BA, Markmann E, Palanjian M, et al. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity? Transplantation 2003;76:1623-5.
18. Wang T, Singh B, Warnock GL, Rajotte RV. Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy. Diabetes 1992;41:114-7.
19. Kin T, Senior P, O'Gorman D, Richer B, Salam A, Shapiro AM. Risk factors for islet loss during culture prior to transplantation. Transpl Int 2008;21:1029-35.
20. Ricordi C, Lacy PE, Scharp DW. Automated islet isolation from human pancreas. Diabetes 1989;38(Suppl 1):140-2. (Pubitemid 19029262)
21. Barbaro B, Salehi P, Wang Y, Qi M, Gangemi A, Kuechle J, et al. Improved human pancreatic islet purification with the refined UIC-UB density gradient. Transplantation 2007;84:1200-3. (Pubitemid 350125364)
22. Ricordi C, Gray DW, Hering BJ, Kaufman DB, Warnock GL, Kneteman NM, et al. Islet isolation assessment in man and large animals. Acta Diabetol Lat 1990;27:185-95. (Pubitemid 20367488)
23. Barnett MJ, McGhee-Wilson D, Shapiro AM, Lakey JR. Variation in human islet viability based on different membrane integrity stains. Cell Transplant 2004;13:481-8. (Pubitemid 39557427)
24. Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 2007;46:324-9. (Pubitemid 47344766)
25. Baskin-Bey ES, Washburn K, Feng S, Oltersdorf T, Shapiro D, Huyghe M. Clinical trial of the pan-caspase inhibitor, IDN-6556, in human liver preservation injury. Am J Transplant 2007;7:218-25. (Pubitemid 44952876)
26. Kin T, Zhai X, Murdoch TB, Salam A, Shapiro AM, Lakey JR. Enhancing the success of human islet isolation through optimization and characterization of pancreas dissociation enzyme. Am J Transplant 2007;7:1233-41. (Pubitemid 46643110)
27. Campbell PM, Salam A, Ryan EA, Senior P, PatyBW, Bigam D, et al. Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. Am J Transplant 2007;7:1242-8. (Pubitemid 46643123)
28. Campbell PM, Senior PA, Salam A, Labranche K, Bigam DL, Kneteman NM, et al. High risk of sensitization after failed islet transplantation. Am J Transplant 2007;7:2311-7. (Pubitemid 47347848)
29. Strom TB. Saving islets from allograft rejection. Proc Natl Acad Sci U S A 2005;102:12651-2. (Pubitemid 41279418)
30. Kim HI, Yu JE, Park CG, Kim SJ. Comparison of four pancreatic islet implantation sites. J Korean Med Sci 2010;25:203-10.
31. Juszczak MT, Kooner P, Pawelec K, Jones GL, Hughes SJ, Kumar A, et al. Highly selective intraportal transplantation of pancreatic islets. J Surg Res 2009;157:216-22.